This certification against the EXCiPACT GMP standard demonstrates Mitsubishi's commitment to delivering safe, high quality pharmaceutical excipients to the market. The scope covers Mitsubishi's manufacturing of polyvinyl alcohol used in numerous pharmaceutical products.
Neil Willings, SGS International Sales/Accounts Head, said: "Mitsubishi Chemical Corporation belongs to the growing number of companies who choose to be responsive to the growing needs of the pharmaceutical supply chain. We are pleased to take part in this sustainable milestone, since we were also given the opportunity to promote the value of certification and standards. Mitsubishi and SGS shared the aim of ensuring safety, risk-reduction and quality in the process."
SGS and Mitsubishi auditors entered a rigorous assessment process to achieve EXCiPACT registration. The auditors completed the two-day EXCiPACT Auditor Training Course and post-course examination to meet the required standard. The certificate issued by SGS was also verified by an independent certification board before being issued.
The EXCiPACT Certification Scheme simplifies pharmaceutical company audits. Since GMP and/or GDP compliance requires increased audit complexity, this scheme provides simpler methodologies to allow drug manufacturers to achieve compliance more easily.
For full details of all sites that have been EXCiPACT certified to date in 17 Countries, visit EXCiPACT Certificate Holders.
For more information, please contact:
Sr. Global Marketing Manager
Certification and Business Enhancement
t: +201 448 0377
SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 97,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.